Abstract:What's New? Glucocorticoids are used to help reduce side effects associated with high‐dose chemotherapy. Recent evidence suggests, however, that glucocorticoids negatively impact the efficacy of chemotherapy and promote tumor progression. Here, in colorectal cancer (CRC) cells, investigation of mechanisms underlying the metastasis‐inducing effects of glucocorticoids shows that following glucocorticoid exposure, migration rates vary considerably in CRC cells with different glucocorticoid receptor (GR) expression levels. GRs were found to interact with ten‐eleven translocation enzymes (TETs), linking glucocorticoid signaling and epigenetic regulation. Co‐targeting of GR and TET with belinostat resulted in down‐regulation of metastasis‐associated genes, offering additional insight into relationships between glucocorticoids and cancer. Glucocorticoids (GCs), commonly used for anti‐inflammatory and cancer treatments, have been linked to the promotion of cancer metastasis. Yet, the molecular mechanisms behind this potential remain poorly understood. Clarifying these mechanisms is crucial for a nuanced understanding and potential refinement of GC therapies in the context of cancer treatment. In HEK293T cells, co‐immunoprecipitation (Co‐IP) and chromatin immunoprecipitation sequencing (ChIP‐seq) were used with antibodies of glucocorticoid receptor (GR) and ten‐eleven translocation enzymes (TET) family proteins (TET1, TET2, TET3). Drug repositioning was performed through the Connectivity Map database, using common target genes of GR and TET2 in HEK293 and HCT116 cell lines and differentially expressed genes (DEGs) of colorectal cancer (CRC). Cell migration and invasion were tested in CRC cell lines with varying GR expression, that is, HCT116 and HT29 cell lines. Dexamethasone (Dex) treatment resulted in a significant difference in cell migration rates in two CRC cell lines with disparate GR expression levels. Co‐IP and ChIP‐seq analyses substantiated the interaction between GR and TET family proteins in HEK293T cells. Belinostat, the selected compound, was successfully validated for its potential to counteract the effects of GC‐induced invasion in CRC cells in vitro. Transcriptomic analyses of Belinostat‐treated HCT116 cells revealed down‐regulation of target genes associated with cancer metastasis. This study provides valuable insights into the molecular mechanisms underlying GC‐induced metastasis, introducing newly repositioned compounds that could serve as potential adjuvant therapy to GC treatment. Furthermore, it opens avenues for exploring novel drug candidates for CRC treatment.

Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells

Corticosteroids Induce Chemotherapy Resistance in the Majority of Tumour Cells from Bone, Brain, Breast, Cervix, Melanoma and Neuroblastoma.

Corticosteroid Co-Treatment Induces Resistance to Chemotherapy in Surgical Resections, Xenografts and Established Cell Lines of Pancreatic Cancer

Glucocorticoid-Mediated Inhibition of Chemotherapy in Ovarian Carcinomas

Dexamethasone Disrupts Cytoskeleton Organization and Migration of T47D Human Breast Cancer Cells by Modulating the AKT/mTOR/RhoA Pathway.

Abstract B098: Impact of dexamethasone on chemotherapy response in ovarian cancer

Abstract 5058: Impact of dexamethasone on chemotherapy response in ovarian cancer

Dexamethasone Enhances Programmed Cell Death 1 (PD-1) Expression During T Cell Activation: an Insight into the Optimum Application of Glucocorticoids in Anti-Cancer Therapy

Dexamethasone As A Chemosensitizer for Breast Cancer Chemotherapy: Potentiation of the Antitumor Activity of Adriamycin, Modulation of Cytokine Expression, and Pharmacokinetics

Cancer Cell Membrane-Enveloped Dexamethasone Normalizes the Tumor Microenvironment and Enhances Gynecologic Cancer Chemotherapy

Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer

HMGB1 Knockdown Increases MM Cell Vulnerability by Regulating Autophagy and DNA Damage Repair

Activation of Glucocorticoid Receptor Inhibits the Stem-Like Properties of Bladder Cancer Via Inactivating the Β-Catenin Pathway.

Glucocorticoids Mediate Drug Resistance: Mechanisms And Its Clinical Impact

Dexamethasone inhibits pancreatic tumor growth in preclinical models: Involvement of activating glucocorticoid receptor

Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway

Glucocorticoid promotes metastasis of colorectal cancer via co‐regulation of glucocorticoid receptor and TET2

Glucocorticoid Reduces Pemetrexed Sensitivity by Mediating Senescence-Associated Secretory Phenotype in Bcl-2 Dependent Manner in Non-Small-Cell Lung Cancer

Dexamethasone Inhabits the Therapeutic Effect of Paclitaxel Against Human Ovarian Xenograft Tumors

Involvement Of Small G Protein Rhob In The Regulation Of Proliferation, Adhesion And Migration By Dexamethasone In Osteoblastic Cells

[Effect of Dexamethasone on Cisplatin Induced Apoptosis in Primary Cells from Resected Specimens with Chinese Human Lung Adenocarcinoma Ex Vivo].